Zheng Quan Shi Bao Wang·2025-11-14 09:28Core Viewpoint - The Helicobacter pylori concept sector has seen a 1.50% increase, ranking fifth among concept sectors, with significant contributions from stocks like Kangzhi Pharmaceutical and Haichen Pharmaceutical reaching a 20% limit up [1][2]. Group 1: Market Performance - The Helicobacter pylori concept sector had 48 stocks rising, with notable limit-up performances from Kangzhi Pharmaceutical and Haichen Pharmaceutical [1]. - The top gainers in the sector included Kangwei Century, Anglikang, and Olin Bio, with increases of 8.60%, 5.52%, and 4.29% respectively [1]. - Conversely, the stocks with the largest declines included Zhongke Technology, Botuo Bio, and Jilin Aodong, which fell by 5.75%, 2.68%, and 2.06% respectively [1]. Group 2: Capital Inflow - The Helicobacter pylori concept sector attracted a net inflow of 1.583 billion yuan, with 34 stocks receiving net inflows, and 9 stocks exceeding 30 million yuan in net inflow [2]. - The leading stock in terms of net inflow was Zhongsheng Pharmaceutical, which saw a net inflow of 732 million yuan, followed by Haichen Pharmaceutical and Te Yi Pharmaceutical, each with 299 million yuan [2]. - The net inflow ratios for Zhongsheng Pharmaceutical, Haichen Pharmaceutical, and Kangzhi Pharmaceutical were 36.05%, 21.08%, and 20.78% respectively [3].